Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 12, 2024
Daily News
January 12, 2024
- Ono Poised to Overcome Opdivo Patent Cliff and Go Fully Global under New President
January 12, 2024
- 80-90% of Clinics in Northern Noto Not Functioning: JMA Official
January 12, 2024
- Daiichi Sankyo Healthcare to Launch Calonal OTC, Ayumi to Focus on Rx
January 12, 2024
- Santen Curbs Cosopt Mini Shipments after Quake, Nitto Medic to Re-Supply All Products
January 12, 2024
- Japan Designates Noto Peninsula Quake as Severe Disaster
January 12, 2024
- Japan Ethical Drug Sales Up 2.2% in November: Crecon
January 12, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…